Senzar Asset Management Raised Its Abbott Labs (ABT) Holding; Allscripts Healthcare Solutions Has 1.45 Sentiment

November 28, 2017 - By Kurt Siggers

Allscripts Healthcare Solutions, Inc. delivers information technology (IT) solutions and services to help healthcare organizations. The company has market cap of $2.55 billion. The Firm operates through three divisions: Clinical and Financial Solutions, Population Health, and Netsmart. It currently has negative earnings. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions.

Senzar Asset Management Llc increased Abbott Labs (ABT) stake by 16.52% reported in 2017Q2 SEC filing. Senzar Asset Management Llc acquired 63,900 shares as Abbott Labs (ABT)’s stock declined 3.42%. The Senzar Asset Management Llc holds 450,700 shares with $21.91 million value, up from 386,800 last quarter. Abbott Labs now has $97.51B valuation. The stock decreased 0.23% or $0.13 during the last trading session, reaching $56.02. About 6.65M shares traded or 26.43% up from the average. Abbott Laboratories (NYSE:ABT) has risen 15.90% since November 28, 2016 and is uptrending. It has underperformed by 0.80% the S&P500.

Since June 15, 2017, it had 0 insider buys, and 1 insider sale for $26,482 activity. Watkin Jared also sold $26,482 worth of Abbott Laboratories (NYSE:ABT) on Thursday, June 15.

Among 24 analysts covering Abbott Laboratories (NYSE:ABT), 14 have Buy rating, 0 Sell and 10 Hold. Therefore 58% are positive. Abbott Laboratories had 87 analyst reports since July 24, 2015 according to SRatingsIntel. The company was maintained on Thursday, October 19 by BMO Capital Markets. The stock of Abbott Laboratories (NYSE:ABT) earned “Equal-Weight” rating by Morgan Stanley on Monday, January 4. The rating was maintained by Barclays Capital with “Overweight” on Thursday, September 28. RBC Capital Markets maintained Abbott Laboratories (NYSE:ABT) rating on Thursday, October 19. RBC Capital Markets has “Buy” rating and $60.0 target. BMO Capital Markets maintained the stock with “Hold” rating in Thursday, August 31 report. BTIG Research reinitiated the stock with “Buy” rating in Wednesday, June 21 report. The stock of Abbott Laboratories (NYSE:ABT) earned “Neutral” rating by UBS on Tuesday, September 22. On Tuesday, August 15 the stock rating was maintained by Cowen & Co with “Buy”. The firm has “Market Perform” rating given on Friday, January 29 by William Blair. As per Friday, October 9, the company rating was maintained by RBC Capital Markets.

Investors sentiment decreased to 0.88 in Q2 2017. Its down 0.75, from 1.63 in 2017Q1. It is negative, as 69 investors sold ABT shares while 545 reduced holdings. 102 funds opened positions while 441 raised stakes. 1.22 billion shares or 0.83% more from 1.21 billion shares in 2017Q1 were reported. 93,985 were reported by Callahan Advsr Limited Co. The New Jersey-based Mcrae Capital has invested 0.18% in Abbott Laboratories (NYSE:ABT). Virtus Invest Advisers Inc has invested 0.18% of its portfolio in Abbott Laboratories (NYSE:ABT). Cypress Capital Mgmt Ltd Liability (Wy) holds 0% or 2,531 shares. State Of Tennessee Treasury Department accumulated 0.24% or 1.03 million shares. Aimz Inv Advsr accumulated 19,649 shares or 0.8% of the stock. Private Harbour Inv Management Counsel Ltd Liability Corp holds 1.8% or 44,995 shares. Legacy Private holds 0.03% in Abbott Laboratories (NYSE:ABT) or 4,141 shares. The California-based Private Ocean Limited has invested 0.04% in Abbott Laboratories (NYSE:ABT). First Western has invested 2.41% in Abbott Laboratories (NYSE:ABT). Private Trust Na reported 0.69% of its portfolio in Abbott Laboratories (NYSE:ABT). Independent Port Consultants owns 1,982 shares or 0.04% of their US portfolio. Samlyn Cap Lc has 1.08 million shares. Miller Inv Mngmt Ltd Partnership has invested 0.2% of its portfolio in Abbott Laboratories (NYSE:ABT). Charter Tru Communication holds 177,746 shares or 1.04% of its portfolio.

Analysts await Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) to report earnings on February, 15. They expect $0.13 earnings per share, up 30.00% or $0.03 from last year’s $0.1 per share. MDRX’s profit will be $23.53 million for 27.10 P/E if the $0.13 EPS becomes a reality. After $0.12 actual earnings per share reported by Allscripts Healthcare Solutions Inc for the previous quarter, Wall Street now forecasts 8.33% EPS growth.

Blue Harbour Group L.P. holds 4.58% of its portfolio in Allscripts Healthcare Solutions Inc for 9.31 million shares. Glenhill Advisors Llc owns 5.51 million shares or 4.43% of their US portfolio. Moreover, Adirondack Research & Management Inc. has 2.85% invested in the company for 574,033 shares. The New York-based Paradigm Capital Management Inc Ny has invested 2.25% in the stock. S&T Bank Pa, a Pennsylvania-based fund reported 705,807 shares.